Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer.
Biochem Soc Trans
; 49(5): 2381-2395, 2021 11 01.
Article
en En
| MEDLINE
| ID: mdl-34515749
ABSTRACT
The discovery of a new class of small molecule compounds that target the BCL-2 family of anti-apoptotic proteins is one of the great success stories of basic science leading to translational outcomes in the last 30 years. The eponymous BCL-2 protein was identified over 30 years ago due to its association with cancer. However, it was the unveiling of the biochemistry and structural biology behind it and its close relatives' mechanism(s)-of-action that provided the inspiration for what are now known as 'BH3-mimetics', the first clinically approved drugs designed to specifically inhibit protein-protein interactions. Herein, we chart the history of how these drugs were discovered, their evolution and application in cancer treatment.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Sistemas de Liberación de Medicamentos
/
Proteínas Proto-Oncogénicas c-bcl-2
/
Descubrimiento de Drogas
/
Antineoplásicos
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Biochem Soc Trans
Año:
2021
Tipo del documento:
Article
País de afiliación:
Australia